February 3-5th 2021 :
Defymed is very happy to announce its participation in the EAHAD (European Association for Haemophilia and Allied Disorders) virtual congress which will take place from February 3 to 5, 2021.
This event is an opportunity for Defymed to identify potential partners and to place itself in the hemophilia sector, one of the applications of the MailPan® device. Even if the congress is virtual, Deyfmed would like to take the opportunity to establish a strong network in Europe in the field of Hemophilia disorders.
This congress aims to improve the situation of patients with hemophilia or other blood clotting disorders. For, the association wishes to offer clinical care adapted to patients, to make hemophilia known to doctors and the population, and finally by highlighting research in this environment. For Defymed, participation to EAHAD is a real chance to receive the knowledge from world experts on the latest developments in Hemophilia and bleeding disorders.
Defymed’s objective is to adapt MailPan® technology to Hemophilia A treatment thanks to a macro-encapsulation of factor VIII secreting cells. Thanks to this therapeutic solution, Defymed’s aim to solve Hemophilia A unmet medical needs by preventing the need of factor injections and eliminating spontaneous bleeding which is the most dangerous complication for Hemophilia A patients.
Elisa Maillard – Pedracini, our Chief Scientific Officer, will follow the conference online.
For more info
If you want to meet us, do not hesitate to contact us at : email@example.com